Bernstein Liebhard LLP Reports On FDA Panels’ Safety Review Of Fosamax

Share Article

Bernstein Liebhard LLP reports that two advisory panels of the U.S. Food and Drug Administration will convene on September 9, 2011 to review the safety and effectiveness of Fosamax and other bisphosphonates.

On September 9, 2011, two advisory panels of the U.S. Food and Drug Administration (“FDA”) will meet to discuss whether to issue a recommendation that would require Fosamax and other bisphosphonate users to take a “drug holiday” or recommend that time restrictions be placed on their treatment period. Additionally, the panels will confer as to whether Fosamax and similar medications are safe and effective for long-term use. In July, prompted by a wave of recent studies suggesting that long-term use of drugs such as Fosamax puts patients at an increased risk for sustaining atypical femur fractures, the FDA announced that a joint meeting of advisory committees* on drug safety and reproductive health would meet to conduct a safety review. The lawyers at Bernstein Liebhard LLP are hopeful that the outcome of the committee meeting will result in the FDA imposing a stronger warning on the drugs’ labeling or a restriction on the amount of time that medications like Fosamax can be used.    

FDA Review Process Coincides With Commencement Of Fosamax Bellwether Trial

In addition to the FDA’s safety review, a bellwether Fosamax trial will commence in the U.S. District Court for the Southern District of New York this week. The consolidated litigation, In re Fosamax Products Liability Litigation, is currently pending before Judge John F. Keenan (“MDL No. 1789”). Merck, the manufacturer of Fosamax, is currently defending thousands of lawsuits filed by injured individuals who claim that the company failed to adequately warn consumers of the potential side effects associated with Fosamax use.

Previous FDA Warning Regarding Fosamax Femur Fractures

In October 2010, the FDA issued a warning** that Fosamax and other bisphosphonates put patients at risk for atypical thigh bone (femur) fractures. Since that time, Bernstein Liebhard LLP has provided a wealth of consumer information concerning the risks associated with Fosamax use on its website, http://www.consumerinjurylawyers.com. If you or a loved one took Fosamax and sustained a femur fracture, you may be entitled to compensation for medical bills, pain and suffering, lost wages and other injuries.

  • fda.gov/AdvisoryCommittees/Calendar/ucm262477.htm

** fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm229171.htm

For more information about filing a Fosamax femur fracture lawsuit, contact an attorney at Bernstein Liebhard LLP at (877) 779-1414 or at info(at)consumerinjurylawyers(dot)com.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414
http://www.consumerinjurylawyers.com
http://www.bernlieb.com

ATTORNEY ADVERTISING. © 2011 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
consumerinjurylawyers.com

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Visit website